News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CeNeS Pharmaceuticals PLC (CEN.L): Clinical Trial Results; Positive Preliminary Results With M6G From Phase III Trial In Post-Operative Pain



10/19/2005 5:11:29 PM

CeNeS Pharmaceuticals plc (LSE: CEN) ("CeNeS" or "the Company") today announced positive preliminary results in a Phase III clinical trial to assess the efficacy of M6G (morphine-6-glucuronide) as an analgesic in patients suffering from post-operative pain (p less than 0.05). The Phase III study also confirmed the effective dose of M6G and supported the findings of earlier volunteer and Phase II studies that M6G treated patients suffer less nausea and vomiting when compared to patients receiving morphine.

Read at Prime Zone

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES